scholarly journals Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers

EBioMedicine ◽  
2021 ◽  
Vol 66 ◽  
pp. 103329
Author(s):  
Guanglin Cui ◽  
Qingbo Fan ◽  
Zhenfeng Li ◽  
Rasmus Goll ◽  
Jon Florholmen
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Therapeutic Response ◽  
Novel Biomarkers ◽  
Inflammatory Bowel

Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalised medicine in its infancy

2018 ◽  
Vol 48 (11-12) ◽  
pp. 1213-1231 ◽  
Author(s):  
Toer W. Stevens ◽  
Mijntje Matheeuwsen ◽  
Maria H. Lönnkvist ◽  
Claire E. Parker ◽  
Manon E. Wildenberg ◽  
...  
Keyword(s):  
Systematic Review ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Therapeutic Response ◽  
Personalised Medicine ◽  
Predictive Biomarkers ◽  
Inflammatory Bowel

scholarly journals The Possible Role of the Novel Cytokines IL-35 and IL-37 in Inflammatory Bowel Disease

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Yanmei Li ◽  
Yanan Wang ◽  
Ying Liu ◽  
Yatian Wang ◽  
Xiuli Zuo ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Healthy Subjects ◽  
Inflammatory Diseases ◽  
Inflammatory Cells ◽  
Intestinal Epithelial ◽  
Gene Expressions ◽  
Expression Studies ◽  
Novel Biomarkers ◽  
Inflammatory Bowel

Interleukin- (IL-) 35 and IL-37 are newly discovered immune-suppressing cytokines. They have been described in inflammatory diseases such as collagen-induced arthritis and asthma. However, their expressions in inflammatory bowel disease (IBD) patients have not been yet explored. Our aim was to evaluate serum and inflamed mucosal levels in IBD patients. In 20 ulcerative colitis (UC) patients, 7 Crohn’s disease (CD) patients, and 15 healthy subjects, cytokine levels in serum were determined using ELISA and mucosal expression studies were performed by immunohistochemistry, quantitative real-time PCR, and Western blot. The results showed that serums IL-35 and IL-37 levels were significantly decreased in UC and CD patients compared with healthy subjects. The cytokines levels correlated inversely with UC activity. IL-35 was expressed in infiltrating immune cells while IL-37 in intestinal epithelial cells as well as inflammatory cells. IBD patients had significantly higherEbi3,p35(two subunits of IL-35), andIL-37bgene expressions; IL-35 and IL-37 protein expressions were higher in IBD patients compared with controls. The study showed that serums IL-35 and IL-37 might be potentially novel biomarkers for IBD. Intestinal IL-35 and IL-37 proteins are upregulated, suggesting that regulating the expression of the two cytokines may provide a new possible target for the treatment of IBD.

scholarly journals Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease

2012 ◽  
Vol 3 (2) ◽  
pp. e10 ◽  
Author(s):  
Corinne Cayatte ◽  
Barbara Joyce-Shaikh ◽  
Felix Vega ◽  
Katia Boniface ◽  
Jeffrey Grein ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Therapeutic Response ◽  
Inflammatory Bowel

Sa1200 Identifying Crohn's Disease Cases for Clinical Trials: Data From the Novel Biomarkers in Inflammatory Bowel Disease (NBIBD) Project Cohort

2013 ◽  
Vol 144 (5) ◽  
pp. S-228
Author(s):  
James D. Falvey ◽  
Teagan S. Hoskin ◽  
Berrie Meijer ◽  
Anna L. Ashcroft ◽  
Mark B. Hampton ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Clinical Trials ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Bowel Disease ◽  
The Novel ◽  
Novel Biomarkers ◽  
Inflammatory Bowel

scholarly journals Metabolomics facilitate the personalized management in inflammatory bowel disease

2021 ◽  
Vol 14 ◽  
pp. 175628482110644
Author(s):  
Rirong Chen ◽  
Jieqi Zheng ◽  
Li Li ◽  
Chao Li ◽  
Kang Chao ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Disease Activity ◽  
Bowel Disease ◽  
Therapeutic Response ◽  
Gastrointestinal Disorder ◽  
Response Prediction ◽  
Personalized Management ◽  
Inflammatory Bowel ◽  
Histological Activity ◽  
Qualitative And Quantitative Study

Inflammatory bowel disease (IBD) is a gastrointestinal disorder characterized by chronic relapsing inflammation and mucosal lesions. Reliable biomarkers for monitoring disease activity, predicting therapeutic response, and disease relapse are needed in the personalized management of IBD. Given the alterations in metabolomic profiles observed in patients with IBD, metabolomics, a new and developing technique for the qualitative and quantitative study of small metabolite molecules, offers another possibility for identifying candidate markers and promising predictive models. With increasing research on metabolomics, it is gradually considered that metabolomics will play a significant role in the management of IBD. In this review, we summarize the role of metabolomics in the assessment of disease activity, including endoscopic activity and histological activity, prediction of therapeutic response, prediction of relapse, and other aspects concerning disease management in IBD. Furthermore, we describe the limitations of metabolomics and highlight some solutions.

Sign in / Sign up

Export Citation Format

Share Document